Precision BioSciences, Inc. (NASDAQ:DTIL)’s stock price gapped down prior to trading on Friday . The stock had previously closed at $13.46, but opened at $12.99. Precision BioSciences shares last traded at $13.00, with a volume of 2,400 shares trading hands.
A number of brokerages have issued reports on DTIL. TheStreet upgraded Precision BioSciences from a “d+” rating to a “c” rating in a research note on Thursday. Stifel Nicolaus upped their price target on Precision BioSciences from $23.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, September 10th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, Precision BioSciences currently has an average rating of “Buy” and a consensus price target of $22.33.
The business has a 50-day moving average price of $11.27 and a 200 day moving average price of $10.66. The stock has a market cap of $752.47 million, a PE ratio of -13.88 and a beta of 1.73.
Institutional investors and hedge funds have recently modified their holdings of the stock. Lazard Asset Management LLC purchased a new stake in Precision BioSciences during the 2nd quarter worth about $86,000. SG Americas Securities LLC purchased a new stake in Precision BioSciences during the 1st quarter worth about $103,000. E Fund Management Co. Ltd. purchased a new stake in Precision BioSciences during the 1st quarter worth about $122,000. Texas Yale Capital Corp. purchased a new stake in Precision BioSciences during the 2nd quarter worth about $125,000. Finally, Advisor Group Holdings Inc. lifted its holdings in Precision BioSciences by 38.2% during the 2nd quarter. Advisor Group Holdings Inc. now owns 9,982 shares of the company’s stock worth $125,000 after purchasing an additional 2,757 shares in the last quarter. 47.80% of the stock is currently owned by institutional investors and hedge funds.
Precision BioSciences Company Profile (NASDAQ:DTIL)
Precision BioSciences, Inc is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases.
Read More: Trading signals using Bollinger bands
Receive News & Ratings for Precision BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.